Clopimozide
Clopimozide.svg
Clinical data
ATC code
  • none
Identifiers
  • 3-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidyl]-6-chloro-1H-benzimidazol-2-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H28ClF2N3O
Molar mass496.00 g·mol−1
3D model (JSmol)
  • Fc1ccc(cc1)C(c2ccc(F)cc2)CCCN5CCC(N4c3ccc(Cl)cc3NC4=O)CC5
  • InChI=1S/C28H28ClF2N3O/c29-21-7-12-27-26(18-21)32-28(35)34(27)24-13-16-33(17-14-24)15-1-2-25(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24-25H,1-2,13-17H2,(H,32,35)
  • Key:JCZYXTVBWHAWLL-UHFFFAOYSA-N

Clopimozide (R-29,764) is a typical antipsychotic drug of the diphenylbutylpiperidine class.[1][2] It is very potent and has an extremely long duration of action, lasting at least one week with a single dose.[3][4][5] It was developed by Janssen Pharmaceutica but was never marketed.

See also

References

  1. ^ De Cuyper HJ, Van Praag HM, Mulder WR (May 1979). "Therapeutical significance of clopimozide in the treatment of chronic psychotic patients". Acta Psychiatrica Scandinavica. 59 (5): 561–74. doi:10.1111/j.1600-0447.1979.tb00256.x. PMID 37697. S2CID 30954603.
  2. ^ Knapen J, Bollen J, Brugmanns J, Rombaut N (1976). "[Treatment of chronic psychoses with oral clopimozide]". Acta Psychiatrica Belgica (in French). 76 (4): 644–57. PMID 798469.
  3. ^ Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Wauquier A (August 1975). "Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series". Arzneimittel-Forschung. 25 (8): 1287–94. PMID 1242360.
  4. ^ Floru L, Tegeler J (1978). "Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764)". Arzneimittel-Forschung. 28 (2): 341–4. PMID 25071.
  5. ^ Bobon J, Parent M, Toussaint C, Pinchard A (1976). "[Long-acting neuroleptics. IV. Preliminary study of clopimozide (R 29764)]". Acta Psychiatrica Belgica (in French). 76 (1): 138–43. PMID 970182.